Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bayer Joins $162 Million Round for Ji Xing; Has Preferential Rights for In-Licensings

publication date: Jan 11, 2024

German’s Bayer AG joined with RTW Investments of New York City to make a $162 million D round investment into Ji Xing Pharma, an innovative Shanghai drug development company. In exchange for its $35 million share of the funding, Bayer will have privileged rights to negotiate products from RTW’s portfolio of cardiovascular and ophthalmology candidates. Bayer said the investment has the potential to expand its already strong portfolio in cardiovascular and ophthalmology, along with its China presence. Founded in 2019, Ji Xing is backed by RTW and partners with global biotechnology companies to develop innovative therapeutics for cardiovascular and ophthalmology indications. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital